Richard Pzena
Pzena Investment Management
Richard Pzena Takeda Pharmaceutical Co Ltd ADR stake
total: 584
Pzena Investment Management TAK trades
- Total transactions:
- 3
- New positions:
- 1
- Added:
- 2
- Held since:
- 2025 Q4
- Held for:
- 3 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Richard Pzena holds 37,820 Takeda Pharmaceutical Co Ltd ADR (TAK) shares with a market value of roughly $606.25K accounting for 0.00% of the overall portfolio. To date, the estimated cost basis is nearly $16.3 for "buy" trades. Pzena Investment Management first purchased TAK in 2025 Q4, initially acquiring 20,627 shares. Since the initial investment in Takeda Pharmaceutical Co Ltd ADR (TAK), Pzena Investment Management has made 2 more transactions.
When did Richard Pzena buy Takeda Pharmaceutical Co Ltd ADR (TAK)?
Richard Pzena first invested in Takeda Pharmaceutical Co Ltd ADR (TAK) in 2025 Q4 at the reported quarter-end price of $15.59 per share.
What's the cost basis of Pzena Investment Management's TAK stake?
The estimated cost basis for Takeda Pharmaceutical Co Ltd ADR (TAK) stake is around $16.30 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $16.30
Richard Pzena's historical trades in Takeda Pharmaceutical Co Ltd ADR
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
37,820
|
$16.03
|
$606,253
|
+33.36% (+9,460)
|
+0%
|
|
2026 Q1
|
0.00%
|
28,360
|
$18.52
|
$525,231
|
+37.49% (+7,733)
|
+0%
|
|
2025 Q4
|
0.00%
|
20,627
|
$15.59
|
$321,575
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.